Results 13,301-13,320 of 21,090 for speaker:Alan Kelly
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: I was going to move on to that. Perhaps Mr. McCallion saw my notes.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: That is a serious risk. Just to clarify for the public watching, and for the Minister for Health, is Mr. McCallion saying that the system cannot distinguish between women whom I have described, who have to come in more often, for example every six months or year, and those who come in for a three-year review?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: Is that not a serious problem?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: That is new information and that is a risk.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: Of course. I appreciate that.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: We have been given a figure of 221 but Dr. Scally has said the figure will grow and he is correct. I want to tease that out a bit. Is it correct that the audit stopped on 1 January?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: That is not a good thing.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: It is a bad thing. All the other variables stayed the same. Potentially, there will be more women affected, pro rata? That is why we hear reference to 221 plus. The audit has stopped since 1 January so the figure will have to increase pro rata, given that all other variables are the same. Is that correct?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: I appreciate that. I fully understand all of that. All the variables are the same and we are broadly talking about 221 cases on 1 January 2018. The guts of almost another year have elapsed. With all the variables being the same the total has increasedpro rata. That is the first thing to point out. I do not think Mr. McCallion disagrees with any of that.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: My next point concerns important information which was given to us, which I think was only found towards the end of the Scally report by Karin Denton. In order to be audited one obviously had to have cancer and have had smears taken, but she brought in a variable of which we were publicly never aware, namely, the matter of 18 months.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: Yes. That means a woman had to have had cancer and to have had a smear. If it was under six months everyone understood because it was too close but we did not know that it was between six and 18 months. When it comes to the 221 cases we know the audit has stopped and the variables have stayed the same so the figure will go up because of that, but what we publicly need to know is whether it...
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: I am aware of that.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: It is not the case?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: So Dr. Scally's report is wrong.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: So the minutes are wrong.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: Yes, it is important to clarify it.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: What criteria were used?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: So there was no timeline. It was not even six months, as I understood.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: There was no timeline. That is good information.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: In fairness, Dr. Scally needs to come out and-----